Antiinflammatory Constituents from Eclipta prostrata using RAW264.7 Macrophage Cells
The whole plant extract of Eclipta prostrata and its isolated compounds were tested for their antiinflammatory effects against lipopolysaccharide (LPS)‐induced nitric oxide (NO), prostaglandin E2 (PGE2) and tumor necrosis factor‐alpha (TNF‐α) release in RAW264.7 cells, as well as for the antiinflamm...
Gespeichert in:
| Veröffentlicht in: | Phytotherapy research 2011-09, Vol.25 (9), p.1313-1316 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1316 |
|---|---|
| container_issue | 9 |
| container_start_page | 1313 |
| container_title | Phytotherapy research |
| container_volume | 25 |
| creator | Tewtrakul, Supinya Subhadhirasakul, Sanan Tansakul, Pimpimon Cheenpracha, Sarot Karalai, Chatchanok |
| description | The whole plant extract of Eclipta prostrata and its isolated compounds were tested for their antiinflammatory effects against lipopolysaccharide (LPS)‐induced nitric oxide (NO), prostaglandin E2 (PGE2) and tumor necrosis factor‐alpha (TNF‐α) release in RAW264.7 cells, as well as for the antiinflammatory mechanism of the active compound on mRNA expression. Among the isolated compounds, orobol (5) exhibited the highest activity against NO release with an IC50 value of 4.6 μm, followed by compounds 1, 2 and 4 with IC50 values of 12.7, 14.9 and 19.1 μm, respectively. The IC50 value of compound 5 against PGE2 release was found to be 49.6 μm, whereas it was inactive towards TNF‐α (IC50 > 100 μm). The mechanism of orobol (5) was found to down‐regulate iNOS and COX‐2 mRNA expression in a concentration‐dependent manner. The present study may support the traditional use of Eclipta prostrata for the treatment of inflammatory‐related diseases. Copyright © 2011 John Wiley & Sons, Ltd. |
| doi_str_mv | 10.1002/ptr.3383 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1620021269</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1620021269</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4553-1428c9598bbca029de071827134b94d83aff9d154ff8c4853f12f36b73977a293</originalsourceid><addsrcrecordid>eNp10E1v1DAQBmALgehSkPgFKBckLlk8HjuOj8uqFKTyVS1q1YvlZO1iyFdtR7D_HlcNhQunmcOjmVcvIc-BroFS9npKYY1Y4wOyAqpUCULiQ7KiSkDJob48Ik9i_E4pVYzyx-SIAQJDKldktxmS94PrTN-bNIZDsR2HmHya7ZBi4cLYFydt56dkiimMMQWTtzn64bo431ywiq9l8cG0YZy-mWtbbG3XxafkkTNdtM-WeUy-vj3Zbd-VZ59O3283Z2XLhcASOKtbJVTdNK2hTO0tlVAzCcgbxfc1GufUHgR3rm55LdABc1g1EpWUhik8Jq_u7uZkN7ONSfc-tjmBGew4Rw0Vy-0Aq_6hOWmMwTo9Bd-bcNBA9W2HOneobzvM9MVydW56u7-Hf0rL4OUCTGxN54IZWh__Os4loqTZlXfup-_s4b8P9efd-fJ48T4m--vem_BDVxKl0BcfTzVcvRGXeAX6C_4GKYuVjw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1620021269</pqid></control><display><type>article</type><title>Antiinflammatory Constituents from Eclipta prostrata using RAW264.7 Macrophage Cells</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Tewtrakul, Supinya ; Subhadhirasakul, Sanan ; Tansakul, Pimpimon ; Cheenpracha, Sarot ; Karalai, Chatchanok</creator><creatorcontrib>Tewtrakul, Supinya ; Subhadhirasakul, Sanan ; Tansakul, Pimpimon ; Cheenpracha, Sarot ; Karalai, Chatchanok</creatorcontrib><description>The whole plant extract of Eclipta prostrata and its isolated compounds were tested for their antiinflammatory effects against lipopolysaccharide (LPS)‐induced nitric oxide (NO), prostaglandin E2 (PGE2) and tumor necrosis factor‐alpha (TNF‐α) release in RAW264.7 cells, as well as for the antiinflammatory mechanism of the active compound on mRNA expression. Among the isolated compounds, orobol (5) exhibited the highest activity against NO release with an IC50 value of 4.6 μm, followed by compounds 1, 2 and 4 with IC50 values of 12.7, 14.9 and 19.1 μm, respectively. The IC50 value of compound 5 against PGE2 release was found to be 49.6 μm, whereas it was inactive towards TNF‐α (IC50 > 100 μm). The mechanism of orobol (5) was found to down‐regulate iNOS and COX‐2 mRNA expression in a concentration‐dependent manner. The present study may support the traditional use of Eclipta prostrata for the treatment of inflammatory‐related diseases. Copyright © 2011 John Wiley & Sons, Ltd.</description><identifier>ISSN: 0951-418X</identifier><identifier>EISSN: 1099-1573</identifier><identifier>DOI: 10.1002/ptr.3383</identifier><identifier>PMID: 21312307</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Animals ; Anti-Inflammatory Agents - pharmacology ; Biological and medical sciences ; Cell Line ; Compositae ; Cyclooxygenase 2 - metabolism ; Dinoprostone - metabolism ; Eclipta - chemistry ; Eclipta prostrata ; Flavonoids - pharmacology ; General pharmacology ; inflammatory mediators ; Inhibitory Concentration 50 ; Lipopolysaccharides ; Macrophages - drug effects ; Macrophages - metabolism ; Medical sciences ; Mice ; Nitric Oxide - metabolism ; Nitric Oxide Synthase Type II - metabolism ; orobol ; Pharmacognosy. Homeopathy. Health food ; Pharmacology. Drug treatments ; Plant Extracts - pharmacology ; Tumor Necrosis Factor-alpha - metabolism</subject><ispartof>Phytotherapy research, 2011-09, Vol.25 (9), p.1313-1316</ispartof><rights>Copyright © 2011 John Wiley & Sons, Ltd.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4553-1428c9598bbca029de071827134b94d83aff9d154ff8c4853f12f36b73977a293</citedby><cites>FETCH-LOGICAL-c4553-1428c9598bbca029de071827134b94d83aff9d154ff8c4853f12f36b73977a293</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fptr.3383$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fptr.3383$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24473370$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21312307$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tewtrakul, Supinya</creatorcontrib><creatorcontrib>Subhadhirasakul, Sanan</creatorcontrib><creatorcontrib>Tansakul, Pimpimon</creatorcontrib><creatorcontrib>Cheenpracha, Sarot</creatorcontrib><creatorcontrib>Karalai, Chatchanok</creatorcontrib><title>Antiinflammatory Constituents from Eclipta prostrata using RAW264.7 Macrophage Cells</title><title>Phytotherapy research</title><addtitle>Phytother. Res</addtitle><description>The whole plant extract of Eclipta prostrata and its isolated compounds were tested for their antiinflammatory effects against lipopolysaccharide (LPS)‐induced nitric oxide (NO), prostaglandin E2 (PGE2) and tumor necrosis factor‐alpha (TNF‐α) release in RAW264.7 cells, as well as for the antiinflammatory mechanism of the active compound on mRNA expression. Among the isolated compounds, orobol (5) exhibited the highest activity against NO release with an IC50 value of 4.6 μm, followed by compounds 1, 2 and 4 with IC50 values of 12.7, 14.9 and 19.1 μm, respectively. The IC50 value of compound 5 against PGE2 release was found to be 49.6 μm, whereas it was inactive towards TNF‐α (IC50 > 100 μm). The mechanism of orobol (5) was found to down‐regulate iNOS and COX‐2 mRNA expression in a concentration‐dependent manner. The present study may support the traditional use of Eclipta prostrata for the treatment of inflammatory‐related diseases. Copyright © 2011 John Wiley & Sons, Ltd.</description><subject>Animals</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cell Line</subject><subject>Compositae</subject><subject>Cyclooxygenase 2 - metabolism</subject><subject>Dinoprostone - metabolism</subject><subject>Eclipta - chemistry</subject><subject>Eclipta prostrata</subject><subject>Flavonoids - pharmacology</subject><subject>General pharmacology</subject><subject>inflammatory mediators</subject><subject>Inhibitory Concentration 50</subject><subject>Lipopolysaccharides</subject><subject>Macrophages - drug effects</subject><subject>Macrophages - metabolism</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Nitric Oxide - metabolism</subject><subject>Nitric Oxide Synthase Type II - metabolism</subject><subject>orobol</subject><subject>Pharmacognosy. Homeopathy. Health food</subject><subject>Pharmacology. Drug treatments</subject><subject>Plant Extracts - pharmacology</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><issn>0951-418X</issn><issn>1099-1573</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10E1v1DAQBmALgehSkPgFKBckLlk8HjuOj8uqFKTyVS1q1YvlZO1iyFdtR7D_HlcNhQunmcOjmVcvIc-BroFS9npKYY1Y4wOyAqpUCULiQ7KiSkDJob48Ik9i_E4pVYzyx-SIAQJDKldktxmS94PrTN-bNIZDsR2HmHya7ZBi4cLYFydt56dkiimMMQWTtzn64bo431ywiq9l8cG0YZy-mWtbbG3XxafkkTNdtM-WeUy-vj3Zbd-VZ59O3283Z2XLhcASOKtbJVTdNK2hTO0tlVAzCcgbxfc1GufUHgR3rm55LdABc1g1EpWUhik8Jq_u7uZkN7ONSfc-tjmBGew4Rw0Vy-0Aq_6hOWmMwTo9Bd-bcNBA9W2HOneobzvM9MVydW56u7-Hf0rL4OUCTGxN54IZWh__Os4loqTZlXfup-_s4b8P9efd-fJ48T4m--vem_BDVxKl0BcfTzVcvRGXeAX6C_4GKYuVjw</recordid><startdate>201109</startdate><enddate>201109</enddate><creator>Tewtrakul, Supinya</creator><creator>Subhadhirasakul, Sanan</creator><creator>Tansakul, Pimpimon</creator><creator>Cheenpracha, Sarot</creator><creator>Karalai, Chatchanok</creator><general>John Wiley & Sons, Ltd</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201109</creationdate><title>Antiinflammatory Constituents from Eclipta prostrata using RAW264.7 Macrophage Cells</title><author>Tewtrakul, Supinya ; Subhadhirasakul, Sanan ; Tansakul, Pimpimon ; Cheenpracha, Sarot ; Karalai, Chatchanok</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4553-1428c9598bbca029de071827134b94d83aff9d154ff8c4853f12f36b73977a293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cell Line</topic><topic>Compositae</topic><topic>Cyclooxygenase 2 - metabolism</topic><topic>Dinoprostone - metabolism</topic><topic>Eclipta - chemistry</topic><topic>Eclipta prostrata</topic><topic>Flavonoids - pharmacology</topic><topic>General pharmacology</topic><topic>inflammatory mediators</topic><topic>Inhibitory Concentration 50</topic><topic>Lipopolysaccharides</topic><topic>Macrophages - drug effects</topic><topic>Macrophages - metabolism</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Nitric Oxide - metabolism</topic><topic>Nitric Oxide Synthase Type II - metabolism</topic><topic>orobol</topic><topic>Pharmacognosy. Homeopathy. Health food</topic><topic>Pharmacology. Drug treatments</topic><topic>Plant Extracts - pharmacology</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tewtrakul, Supinya</creatorcontrib><creatorcontrib>Subhadhirasakul, Sanan</creatorcontrib><creatorcontrib>Tansakul, Pimpimon</creatorcontrib><creatorcontrib>Cheenpracha, Sarot</creatorcontrib><creatorcontrib>Karalai, Chatchanok</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Phytotherapy research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tewtrakul, Supinya</au><au>Subhadhirasakul, Sanan</au><au>Tansakul, Pimpimon</au><au>Cheenpracha, Sarot</au><au>Karalai, Chatchanok</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiinflammatory Constituents from Eclipta prostrata using RAW264.7 Macrophage Cells</atitle><jtitle>Phytotherapy research</jtitle><addtitle>Phytother. Res</addtitle><date>2011-09</date><risdate>2011</risdate><volume>25</volume><issue>9</issue><spage>1313</spage><epage>1316</epage><pages>1313-1316</pages><issn>0951-418X</issn><eissn>1099-1573</eissn><abstract>The whole plant extract of Eclipta prostrata and its isolated compounds were tested for their antiinflammatory effects against lipopolysaccharide (LPS)‐induced nitric oxide (NO), prostaglandin E2 (PGE2) and tumor necrosis factor‐alpha (TNF‐α) release in RAW264.7 cells, as well as for the antiinflammatory mechanism of the active compound on mRNA expression. Among the isolated compounds, orobol (5) exhibited the highest activity against NO release with an IC50 value of 4.6 μm, followed by compounds 1, 2 and 4 with IC50 values of 12.7, 14.9 and 19.1 μm, respectively. The IC50 value of compound 5 against PGE2 release was found to be 49.6 μm, whereas it was inactive towards TNF‐α (IC50 > 100 μm). The mechanism of orobol (5) was found to down‐regulate iNOS and COX‐2 mRNA expression in a concentration‐dependent manner. The present study may support the traditional use of Eclipta prostrata for the treatment of inflammatory‐related diseases. Copyright © 2011 John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>21312307</pmid><doi>10.1002/ptr.3383</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0951-418X |
| ispartof | Phytotherapy research, 2011-09, Vol.25 (9), p.1313-1316 |
| issn | 0951-418X 1099-1573 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1620021269 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Animals Anti-Inflammatory Agents - pharmacology Biological and medical sciences Cell Line Compositae Cyclooxygenase 2 - metabolism Dinoprostone - metabolism Eclipta - chemistry Eclipta prostrata Flavonoids - pharmacology General pharmacology inflammatory mediators Inhibitory Concentration 50 Lipopolysaccharides Macrophages - drug effects Macrophages - metabolism Medical sciences Mice Nitric Oxide - metabolism Nitric Oxide Synthase Type II - metabolism orobol Pharmacognosy. Homeopathy. Health food Pharmacology. Drug treatments Plant Extracts - pharmacology Tumor Necrosis Factor-alpha - metabolism |
| title | Antiinflammatory Constituents from Eclipta prostrata using RAW264.7 Macrophage Cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T22%3A10%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiinflammatory%20Constituents%20from%20Eclipta%20prostrata%20using%20RAW264.7%20Macrophage%20Cells&rft.jtitle=Phytotherapy%20research&rft.au=Tewtrakul,%20Supinya&rft.date=2011-09&rft.volume=25&rft.issue=9&rft.spage=1313&rft.epage=1316&rft.pages=1313-1316&rft.issn=0951-418X&rft.eissn=1099-1573&rft_id=info:doi/10.1002/ptr.3383&rft_dat=%3Cproquest_cross%3E1620021269%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1620021269&rft_id=info:pmid/21312307&rfr_iscdi=true |